[{"id":"a0b853c5-b500-4daa-8a24-2f6ed3b6b0bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04788472","created_at":"2021-03-09T15:52:18.670Z","updated_at":"2024-07-02T16:36:33.559Z","phase":"Phase 1/2","brief_title":"Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL","source_id_and_acronym":"NCT04788472","lead_sponsor":"Zhejiang University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19/CD22 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 03/05/2024","primary_completion_date":" 03/05/2024","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2021-03-09"},{"id":"fb803a2a-7774-4825-b1a7-a57d8bc1cad8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04740203","created_at":"2021-02-05T13:56:31.369Z","updated_at":"2024-07-02T16:36:34.977Z","phase":"Phase 1/2","brief_title":"Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL","source_id_and_acronym":"NCT04740203","lead_sponsor":"Zhejiang University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 targeted CAR-T • CD19/CD22 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/31/2021","start_date":" 01/31/2021","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2021-02-05"}]